Brief: Coherus Presents Preliminary Results From Phase I Dose Escalation Study Of Its Anti-Chemokine Receptor 8 Antibody

Coherus Oncology

23/05/2024 23:53

May 23 (Reuters) - Coherus BioSciences Inc  CHRS.O :
    * COHERUS PRESENTS PRELIMINARY RESULTS FROM PHASE I DOSE
ESCALATION STUDY OF ITS ANTI-CHEMOKINE RECEPTOR 8 (CCR8)
ANTIBODY, CHS-114, AT THE 2024 AMERICAN SOCIETY OF CLINICAL
ONCOLOGY (ASCO) ANNUAL MEETING
    * COHERUS BIOSCIENCES: CHS-114 SHOWN TO HAVE ACCEPTABLE
SAFETY
PROFILE WITH NO DOSE-LIMITING TOXICITIES IN HEAVILY PRETREATED
PATIENTS WITH SOLID TUMORS

Source text for Eikon:  ID:nGNX7ZSrpM 
Further company coverage:  CHRS.O 

 ((reuters.briefs@thomsonreuters.com;))